Clinical Trials in Austria / NCT04232553
Active, not recruiting
Phase 3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553 · tracked via the Priya Life Science Austria tracker
Condition(s) studied
Crohn's Disease
Study summary
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Eligibility
Inclusion Criteria:
* Participants must have completed study I6T-MC-AMAG (NCT02891226) or study I6T-MC-AMAM (NCT03926130)
* If female, participant must meet the contraception requirements
Exclusion Criteria:
* Participants must not have developed a new condition, including cancer in the previous study (I6T-MC-AMAG or I6T-MC-AMAM) that would pose an unacceptable risk in the trial.
* Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either previous study.
Note: Participants with a history of active TB with documentation of treatment by the Centers for Disease Control (CDC) and/or World Health Organization (WHO) criteria prior to the originator study are not excluded from the study.
* Participants must not have a known hypersensitivity to any component of mirikizumab or have experienced acute systemic hypersensitivity event with previous study drug administration in the originating study that precludes mirikizumab therapy.
* Participation must not be pregnant, lactating, or planning to become pregnant while enrolled in the study or 16 weeks after receiving the last dose of study drug.
Primary outcome measure(s)
- Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study) — Week 52
Endoscopic Response defined as ≥50% reduction from AMAM study baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. - Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study) — Week 52
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) total score \< (less than) 150. The CDAI measures the severity of active disease using 8 disease variables: stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations, presence or absence of fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight. Each variable is assigned a specific weight/multiplier, and the weighted values are summed to produce a CDAI total score. CDAI total scores can range from 0 to 600, with higher scores indicating more severe disease.
Trial sites (322)
| Facility | City | Region | Status |
|---|---|---|---|
| Digestive Health Specialists | Dothan | Alabama | |
| Research Solutions of Arizona | Litchfield Park | Arizona | |
| Arizona Arthritis & Rheumatology Research, PLLC | Phoenix | Arizona | |
| Care Access - Gilroy | Gilroy | California | |
| Newport Huntington Medical Group | Huntington Beach | California | |
| California Medical Research Associates | Northridge | California | |
| Connecticut Clinical Research Institute | Bristol | Connecticut | |
| Gastroenterology Consultants of Clearwater | Clearwater | Florida | |
| Clinical Research of West Florida, Inc. (Clearwater) | Clearwater | Florida | |
| IHS Health Research | Kissimmee | Florida | |
| Ezy Medical Research | Miami | Florida | |
| Care Access - Orlando | Orlando | Florida | |
| Gastroenterology Associates of Pensacola, PA | Pensacola | Florida | |
| Precision Clinical Research | Sunrise | Florida | |
| USF Health | Tampa | Florida | |
| Alliance Clinical Research of Tampa | Tampa | Florida | |
| Digestive Healthcare of Georgia | Atlanta | Georgia | |
| Gastrointestinal Specialists of Georgia | Marietta | Georgia | |
| Grand Teton Research Group | Idaho Falls | Idaho | |
| Qualmedica Research, LLC | Evansville | Indiana | |
| Indiana University Health University Hospital | Indianapolis | Indiana | |
| Delta Research Partners | Monroe | Louisiana | |
| Capital Digestive Care - Chevy Chase | Chevy Chase | Maryland | |
| Woodholme Gastroenterology Associates - Glen Burnie | Glen Burnie | Maryland | |
| The Digestive Health Center of Michigan (DHCMI) | Chesterfield | Michigan | |
| Revive Research Institute, Inc. | Farmington Hills | Michigan | |
| MNGI Digestive Health - Plymouth Endoscopy Center & Clinic | Plymouth | Minnesota | |
| Washington University Medical School | St Louis | Missouri | |
| Care Access - Las Vegas | Las Vegas | Nevada | |
| Holy Name Medical Center | Teaneck | New Jersey | |
| Clinical & Translational Research Center (CTRC) | Chapel Hill | North Carolina | |
| Carolina Digestive Diseases and Endoscopy Center | Greenville | North Carolina | |
| Care Access - Kinston | Kinston | North Carolina | |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | |
| Ohio Gastroenterology | Columbus | Ohio | |
| Ohio State University | Hilliard | Ohio | |
| North Shore Gastroenterology & Endoscopy Centers | Westlake | Ohio | |
| The University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | |
| University Gastroenterology | Providence | Rhode Island | |
| Gastroenterology Associates of Orangeburg | Orangeburg | South Carolina |
+ 282 more sites — see the full list on the official registry below.
On this site
📄 Omvoh (mirikizumab) drug profile →More Eli Lilly and Company trials in Austria
Other trials for the same condition
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04232553 on ClinicalTrials.gov ↗ ← All trials in Austria